|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,956.40 INR | +1.23% |
|
+1.08% | +13.76% |
| 07-15 | India's Sun Pharma wins South Africa approval to launch generic Ozempic | RE |
| 07-15 | Sun Pharma Wins South Africa Approval for Generic Semaglutide | MT |
| Market Cap | 4,694B 48.68B 42.67B 39.44B 36.27B 68.44B 69.54B 472B 185B 2,297B 183B 179B 7,913B | P/E 2027 * |
35.7x | P/E 2028 * | 30.2x |
|---|---|---|---|---|---|
| Enterprise Value | 4,421B 45.84B 40.18B 37.14B 34.16B 64.45B 65.49B 444B 174B 2,163B 172B 168B 7,452B | EV / Sales 2027 * |
6.76x | EV / Sales 2028 * | 5.97x |
| Free-Float |
44.39% | Yield 2027 * |
0.81% | Yield 2028 * | 0.91% |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | +1.23% | ||
| 1 week | +1.08% | ||
| Current month | +5.04% | ||
| 1 month | +6.42% | ||
| 3 months | +16.77% | ||
| 6 months | +16.77% | ||
| Current year | +13.76% |
| 1 week | 1,910 |  | 1,962.7 |
| 1 month | 1,834 | | 1,962.7 |
| Current year | 1,583.7 | | 1,962.7 |
| 1 year | 1,548 | | 1,962.7 |
| 3 years | 1,068.35 | | 1,962.7 |
| 5 years | 672.55 | | 1,962.7 |
| 10 years | 312 | | 1,962.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 59 | 01/09/2025 | |
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Director of Finance/CFO | 58 | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 01/09/2025 | |
| Director/Board Member | 73 | 25/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.23% | +1.08% | +15.52% | +80.84% | 48.15B | |
| +1.32% | +1.69% | +70.65% | +114.74% | 35.59B | |
| +1.61% | +0.15% | -2.75% | +39.18% | 11.9B | |
| +0.46% | -0.16% | +17.85% | +89.14% | 11.85B | |
| -0.37% | +2.49% | +34.42% | +136.73% | 9.31B | |
| +0.43% | +1.48% | +54.03% | -3.77% | 7.02B | |
| -0.42% | -1.32% | +16.96% | +35.57% | 6.91B | |
| -.--% | +0.14% | - | - | 6.79B | |
| +0.18% | -1.90% | +0.63% | +211.00% | 6.55B | |
| +0.13% | +0.48% | -31.42% | +17.36% | 6.13B | |
| Average | +0.46% | -0.32% | +19.54% | +80.09% | 15.02B | |
| Weighted average by Cap. | +0.86% | -0.56% | +28.37% | +87.02% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 654B 6.78B 5.95B 5.5B 5.05B 9.54B 9.69B 65.71B 25.76B 320B 25.47B 24.91B 1,103B | 729B 7.56B 6.63B 6.13B 5.64B 10.63B 10.8B 73.27B 28.72B 357B 28.4B 27.78B 1,230B |
| Net income | 133B 1.37B 1.21B 1.11B 1.02B 1.93B 1.96B 13.32B 5.22B 64.88B 5.16B 5.05B 224B | 157B 1.62B 1.42B 1.32B 1.21B 2.28B 2.32B 15.73B 6.17B 76.61B 6.1B 5.96B 264B |
| Net Debt | -273B -2.83B -2.48B -2.3B -2.11B -3.98B -4.05B -27.45B -10.76B -134B -10.64B -10.41B -461B | -341B -3.54B -3.1B -2.87B -2.64B -4.98B -5.06B -34.3B -13.45B -167B -13.3B -13.01B -576B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/07/26 | ₹1,956.40 | +1.23% | 1,676,034 |
| 17/07/26 | ₹1,932.60 | -0.90% | 2,475,664 |
| 16/07/26 | ₹1,950.10 | -0.07% | 1,396,189 |
| 15/07/26 | ₹1,951.50 | +0.46% | 2,283,494 |
| 14/07/26 | ₹1,942.60 | +1.10% | 2,822,124 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
